Cancer Support Community launches national program to assist patients with cancer

AmgenThe Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (CDC), the Open to Options program is ready to provide professional counselors who help more people formulate a list of personalized questions and concerns to be taken into the oncologist's office.

"The number and complexity of options for treating cancer can be overwhelming for people," said Vicki Kennedy, Vice President of Program Development & Delivery at the CSC. "The goal of Open to Options is to help people affected by all cancers evaluate their options so they can feel more confident and communicate clearly with their doctor so a decision is made that best fits their individual desires and goals."

"We are delighted to support the Open to Options program as part of our ongoing commitment to empowering patients to take an active role in their care," said Jean Lim Terra, president of the Amgen Foundation. "The resources that the Cancer Support Community provides individuals and families helps to ensure that those affected by cancer have the knowledge and support they need to make the right decisions at the right time."

The program was created in response to CSC research that found the majority of cancer patients are unprepared to make treatment decisions. A CSC pilot study funded by the Centers for Disease Control and Prevention found that 9 out of 10 patients felt that the list of questions, concerns and expectations contributed to a more productive appointment with their doctor and that the oncologist answered most of their questions. The study also showed:

  • A decrease in anxiety about the appointment for most patients
  • Repeat use of the tools and techniques learned
  • Patient and physician satisfaction

"Open to Options helped me prioritize my questions and concerns in a concise, logical order to help me optimize my time with the oncologist," said Trish H., a multiple myeloma patient who participated in the Open to Options pilot. "When I went into his office, I had my concerns printed out and when I left the appointment I knew that I had decided on the treatment option that was right for me."

About the Cancer Support Community
Backed by evidence that the best cancer care includes emotional and social support, the Cancer Support Community offers these services to all people affected by cancer. Likely the largest professionally-led network of cancer support worldwide, the organization delivers a comprehensive menu of personalized and essential services. Because no cancer care plan is complete without emotional and social support, the Cancer Support Community has a vibrant network of community-based centers and online services run by trained and licensed professionals.

In July 2009, The Wellness Community and Gilda's Club Worldwide joined forces to become the Cancer Support Community. The combined organization provides high-quality psychological and social support through a network of nearly 50 local affiliates, more than 100 satellite locations and online.

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made nearly $180 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...